Taro Pharmaceutical Industries (NYSE:TARO) Earns Daily Media Impact Score of 0.22

News coverage about Taro Pharmaceutical Industries (NYSE:TARO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.5478968601414 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

• Taro Pharmaceutical: Solid Cash-Rich Business With No Debt And A Catalyst (seekingalpha.com)
• Taro to Announce First Quarter Results on August 8, 2017 (finance.yahoo.com)
• Taro Pharmaceutical Industries Ltd. (TARO) Given Average Rating of “” by Brokerages (americanbankingnews.com)
• Taro Pharmaceutical Industries Ltd. (TARO) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
• Chemotherapy Induced Acral Erythema Treatment Market : Outlook Continues to Remain Positive by 2016 – 2022 (medgadget.com)

Several equities analysts have issued reports on the stock. TheStreet raised shares of Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Thursday, July 20th. BidaskClub cut shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Finally, Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd.

Taro Pharmaceutical Industries (NYSE TARO) traded down 1.43% during midday trading on Friday, reaching $113.82. 201,542 shares of the company traded hands. Taro Pharmaceutical Industries has a 12 month low of $92.28 and a 12 month high of $146.89. The company’s 50-day moving average price is $114.12 and its 200 day moving average price is $112.67. The firm has a market capitalization of $4.61 billion, a PE ratio of 10.30 and a beta of 0.64.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings data on Monday, May 22nd. The company reported $2.05 earnings per share for the quarter. Taro Pharmaceutical Industries had a return on equity of 23.08% and a net margin of 51.90%. The company had revenue of $196.41 million for the quarter. On average, equities analysts anticipate that Taro Pharmaceutical Industries will post $9.49 earnings per share for the current year.

WARNING: This article was originally posted by [[site]] and is the sole property of of [[site]]. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at [[permalink]].

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.